Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 15/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.48 |
| ▸ | MET | P08581 | 5/20 | 0.48 |
| ▸ | FLT3 | P36888 | 4/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11889377 | 0.87 | MAPK14 (0.59) | KDRAXLCSF1RPDGFRAMET | |
| SCHEMBL573183 | 0.87 | KDR (0.67) | KDRAXLCSF1RPDGFRAPDGFRB | |
| SCHEMBL572495 | 0.85 | KDR (0.62) | KDRAXLCSF1RPDGFRAPDGFRB | |
| SCHEMBL573554 | 0.83 | KDR (0.59) | KDRAXLCSF1RPDGFRAPDGFRB | |
| SCHEMBL3665924 | 0.83 | AXL (0.61) | KDRAXLCSF1RPDGFRAPDGFRB | |
| SCHEMBL5062848 | 0.82 | AXL (0.51) | KDRAXLCSF1RPDGFRAPDGFRB | |
| SCHEMBL572701 | 0.82 | KDR (0.64) | KDRAXLFLT1 | |
| SCHEMBL573374 | 0.82 | AXL (0.56) | KDRAXLCSF1RPDGFRAPDGFRB | |
| SCHEMBL2919897 | 0.82 | AXL (0.60) | KDRAXLCSF1RPDGFRAPDGFRB | |
| SCHEMBL2920638 | 0.82 | AXL (0.51) | KDRAXLCSF1RPDGFRAPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481736-A1 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | Deciphera Pharmaceuticals, LLC. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2148677-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008131276-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | BRAF, RET, KIT | KDR 163/4885AXL 233/4885CSF1R 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.